NanoFar

www.erasmusmundus-nanofar.eu

NanoFar

European Doctorate in nanomedicine and pharmaceutical innovation

Consortium partners

Associate partners

Advancell
Affilogic
Atlanpôle Biotherapies
Biowin
Carlina Technologies
In-Cell-Art
IPSEN
Kitozyme
PHAST
Regentech

CSIR (South Africa)
University of La Plata (Argentina)

Hospitals of Angers, Nantes, Liège,
Santiago de Compostela

Nanomedicine, applying nanotechnology to healthcare, offers very promising possibilities in diagnosis and therapy. This very competitive, multidisciplinary new field of science is a fast-growing discipline spanning the academic, clinical and industrial sectors. To achieve true clinical progress, a new generation of scientists, with the spirit of open innovation, must be trained.

NanoFar is proposed by leading European academic teams working together on the integrative approaches to nanomedicine. This programme was designed to be an innovative harmonised joint Doctorate programme of excellence for the most talented students from EU and non-EU countries.

A three-year PhD thesis, co-supervised by partners in two different countries and including a one-year mobility period, constitutes the core of the research activities and aims to provide each student with the highest level scientific curriculum, complementary skills and culture.

The training activities will allow the students to benefit fully from the complementarity leading-edge science specialisations of each partner:

- Design of nanomedicine devices,
- Applications of nanomedicine for imaging and radiotherapy,
-Interaction between biological systems and artificial nanostructures,
- Nanomedicine in therapy and regenerative medicine,
- Moving nanomedicine from the laboratory to the clinic.

These topics will be explored at every NanoFar summer school held annually in the partners' countries and completed by top-level thematic courses at each university.

Multidisciplinary core skills acquired during the curriculum will enable the young scientists to master, throughout the programme, the translational and bench-to-bedside approaches relevant to nanomedicine.

Transferable skills, including academic language and writing, career management, communication, research environment and context, are a central component of this PhD

From the very beginning of each student's NanoFar PhD, the industrial sector is present, through spin-offs, SMEs, large companies and bioclusters, as well as University hospitals. Experience with industry brings key expertise in quality management, translational research and commercialisation of nanomedecine.
A two-month internship in those sectors improves the professional aptitude and employability of future graduates.

Fair selection and employment opportunities are a priority for the NanoFar consortium.

The language of the programme is English with full opportunities to learn local languages and maximise cross-cultural as well as scientific interactions.

NanoFar accomodates 10 to 15 new PhD students per year (from EU and non-EU countries).

The NanoFar programme will award successful candidates Double Degrees.

Contact:
Prof. Frank BOURY
Institut de Biologie en Santé PBH-IRIS
Rue Larrey, 4
FR - 49933 ANGERS Cedex 9
Email: frank.boury@univ-angers.fr